Swedish Orphan Biovitrum AB

About Swedish Orphan Biovitrum AB

Sobi is a global biopharmaceutical company focused on transforming the lives of people with rare diseases by providing innovative treatments and improving access to care. Their mission is to unlock the potential of breakthrough innovations to enhance everyday life for patients.

Products & Services

Innovative Medicines:Sobi develops innovative treatments for rare diseases, with a strong pipeline to address the high need for approved therapies (only 5% of rare diseases have approved medicines).

Therapies in Haematology:Therapies focused on conditions like Haemophilia, Immune Thrombocytopenia (ITP), Paroxysmal Nocturnal Haemoglobinuria (PNH), and Diffuse Large B-Cell Lymphoma (DLBCL).

Therapies in Immunology:Treatments for immunological disorders including Familial Mediterranean Fever (FMF), Cryopyrin-Associated Periodic Syndromes (CAPS), Haemophagocytic Lymphohistiocytosis (HLH), Respiratory Syncytial Virus (RSV), and Still's Disease.

Specialty Care:Specialized treatments and services for various rare conditions.

TRYNGOLZA® (olezarsen):A therapy recommended for EU approval by CHMP for Familial Chylomicronemia Syndrome (FCS).

Specialties

Rare Diseases Haematology Immunology Specialty Care Innovative Treatments Research & Development

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Share Issue T: - FT: Share Issue	A: 775205 MR: - FA: SEK 775,204.50 FAN: 775205	D: 2025-08-21 FD: 2025-08-21	1 investors
2	RT: Equity Issuance T: - FT: Equity Issuance	A: 900482 MR: - FA: SEK 900,482.19 FAN: 900482	D: 2024-08-29 FD: 2024-08-29	1 investors

Share Issue Latest

2025-08-21

$775K

1 investor (Pro only)

Equity Issuance 2024-08-29

$900K

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

M

Maruxa Diaz

Global Patient Access Associate Director

P

Peter O'Connor

Supply Planning Manager

M

Mariam Murad

Senior Manager, R&D Planning & Analytics

M

Max Ahlborg

IT Infrastructure Specialist

N

Nicole Germershaus

Head of Manufacturing Science & Technology

G

Guido Oelkers

Chief Executive Officer

View 26 more team members with Pro

Unlock Full Team Directory

Recent News